Larry K. Kociolek, MD, MSCI, and Stanford T. Shulman, MD, Author at Infectious Disease Advisor

Biotherapeutics for the Prevention of Clostridium difficile Infection

By

Larry K. Kociolek, MD, MSCI, and Stanford T. Shulman, MD

August 16, 2017

Experts review biotherapeutics for the prevention of C difficile infection, including probiotics, fecal microbiota transplantation, and nontoxigenic C difficile.

Clostridium Difficile

C difficile Treatment and Prevention: Novel Antibiotics and Immunologic Therapies

By

Larry K. Kociolek, MD, MSCI, and Stanford T. Shulman, MD

June 8, 2017

Experts review novel antibiotic therapies that may limit the impact on the gut microbiome, as well as passive immunization products that may bolster the immune response to C difficile toxins and possibly reduce the frequency of toxigenic strains.

Clostridium Difficile

Review of Clostridium difficile Vaccines in Development

By

Larry K. Kociolek, MD, MSCI, and Stanford T. Shulman, MD

March 24, 2017

Drs Kociolek and Shulman, from the division of infectious diseases at the Ann & Robert H. Lurie Children’s Hospital of Chicago in Illinois, review all the current vaccine candidates in development for Clostridium difficile infection.

Larry K. Kociolek, MD, MSCI, and Stanford T. Shulman, MD

All articles by Larry K. Kociolek, MD, MSCI, and Stanford T. Shulman, MD

Biotherapeutics for the Prevention of Clostridium difficile Infection

C difficile Treatment and Prevention: Novel Antibiotics and Immunologic Therapies

Review of Clostridium difficile Vaccines in Development